TY - JOUR
T1 - Increase in treatment of retinopathy of prematurity in the Netherlands from 2010 to 2017
AU - Trzcionkowska, K.
AU - Vehmeijer, W.B.H.J.
AU - Kerkhoff, F.T.
AU - Bauer, N.J.C.
AU - Bennebroek, C.A.M.
AU - Dijk, P.H.
AU - Dijkman, K.P.
AU - van den Dungen, F.A.M.
AU - Eggink, C.A.
AU - Feenstra, R.P.G.
AU - Groenendaal, F.
AU - van Heijst, A.F.
AU - van der Hoeven, M.A.H.B.M.
AU - Kornelisse, R.F.
AU - Kraal-Biezen, E.
AU - Lopriore, E.
AU - Onland, W.
AU - de Lavalette, V.W.R.
AU - van Rijn, L.J.
AU - Schuerman, F.A.B.A.
AU - Simonsz, H.J.
AU - Voskuil-Kerkhof, E.S.M.
AU - Witlox, R.S.G.M.
AU - Termote, J.U.M.
AU - Schalij-Delfos, N.E.
N1 - Funding Information:
This study was supported by the ODAS foundation grant. There were no competing interests. An earlier version of the study was presented as an oral presentation at the 212th Meeting of the Netherlands Ophthalmological Society (NOG) Congress, Maastricht (NL) March 21‐23 2018, at the 44th annual meeting European Paediatric Ophthalmological Society (EPOS), Budapest (HU) September 7‐9 2018 and at the annual meeting of the European Society of Ophthalmology Nice (FR) June 13‐16 2019.
Publisher Copyright:
© 2020 The Authors. Acta Ophthalmologica published by John Wiley & Sons Ltd on behalf of Acta Ophthalmologica Scandinavica Foundation
PY - 2021/2/1
Y1 - 2021/2/1
N2 - Purpose: Compare patients treated for Retinopathy of Prematurity (ROP) in two consecutive periods. Methods: Retrospective inventory of anonymized neonatal and ophthalmological data of all patients treated for ROP from 2010 to 2017 in the Netherlands, subdivided in period (P)1: 1-1-2010 to 31-3-2013 and P2: 1-4-2013 to 31-12-2016. Treatment characteristics, adherence to early treatment for ROP (ETROP) criteria, outcome of treatment and changes in neonatal parameters and policy of care were compared. Results: Overall 196 infants were included, 57 infants (113 eyes) in P1 and 139 (275 eyes) in P2, indicating a 2.1-fold increase in ROP treatment. No differences were found in mean gestational age (GA) (25.9 ± 1.7 versus 26.0 ± 1.7 weeks, p = 0.711), mean birth weight (791 ± 311 versus 764 ± 204 grams, p = 0.967) and other neonatal risk factors for ROP. In P2, the number of premature infants born <25 weeks increased by factor 1.23 and higher oxygen saturation levels were aimed at in most centres. At treatment decision, 59.6% (P1) versus 83.5% (P2) (p = 0.263) infants were classified as Type 1 ROP (ETROP classification). Infants were treated with laser photocoagulation (98 versus 96%) and intravitreal bevacizumab (2 versus 4%). Retreatment was necessary in 10 versus 21 (p = 0.160). Retinal detachment developed in 6 versus 13 infants (p = 0.791) of which 2 versus 6 bilateral (p = 0.599). Conclusion: In period 2, the number of infants treated according to the ETROP criteria (Type 1) increased, the number of ROP treatments, retinal detachments and retreatments doubled and the absolute number of retinal detachments increased. Neonatal data did not provide a decisive explanation, although changes in neonatal policy were reported.
AB - Purpose: Compare patients treated for Retinopathy of Prematurity (ROP) in two consecutive periods. Methods: Retrospective inventory of anonymized neonatal and ophthalmological data of all patients treated for ROP from 2010 to 2017 in the Netherlands, subdivided in period (P)1: 1-1-2010 to 31-3-2013 and P2: 1-4-2013 to 31-12-2016. Treatment characteristics, adherence to early treatment for ROP (ETROP) criteria, outcome of treatment and changes in neonatal parameters and policy of care were compared. Results: Overall 196 infants were included, 57 infants (113 eyes) in P1 and 139 (275 eyes) in P2, indicating a 2.1-fold increase in ROP treatment. No differences were found in mean gestational age (GA) (25.9 ± 1.7 versus 26.0 ± 1.7 weeks, p = 0.711), mean birth weight (791 ± 311 versus 764 ± 204 grams, p = 0.967) and other neonatal risk factors for ROP. In P2, the number of premature infants born <25 weeks increased by factor 1.23 and higher oxygen saturation levels were aimed at in most centres. At treatment decision, 59.6% (P1) versus 83.5% (P2) (p = 0.263) infants were classified as Type 1 ROP (ETROP classification). Infants were treated with laser photocoagulation (98 versus 96%) and intravitreal bevacizumab (2 versus 4%). Retreatment was necessary in 10 versus 21 (p = 0.160). Retinal detachment developed in 6 versus 13 infants (p = 0.791) of which 2 versus 6 bilateral (p = 0.599). Conclusion: In period 2, the number of infants treated according to the ETROP criteria (Type 1) increased, the number of ROP treatments, retinal detachments and retreatments doubled and the absolute number of retinal detachments increased. Neonatal data did not provide a decisive explanation, although changes in neonatal policy were reported.
KW - extreme
KW - guideline
KW - infants born
KW - laser photocoagulation
KW - outcomes
KW - oxygen
KW - retinopathy of prematurity
KW - treatment
KW - OXYGEN
KW - EXTREME
KW - INFANTS BORN
KW - OUTCOMES
U2 - 10.1111/aos.14501
DO - 10.1111/aos.14501
M3 - Article
C2 - 32701185
SN - 1755-375X
VL - 99
SP - 97
EP - 103
JO - Acta Ophthalmologica
JF - Acta Ophthalmologica
IS - 1
ER -